Loading cancer entity…
Loading cancer entity…
Clinical trials
227 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (55)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03174197 | Atezolizumab in Combination With Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma | completed | Phase 1 / Phase 2 | 60 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT04396860 | Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma | completed | Phase 2 / Phase 3 | 159 | National Cancer Institute (NCI)NIH | 1 |
| Apr 22, 2026 |
| clinicaltrials |
| NCT04817254 | Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma | completed | Phase 2 | 47 | National Cancer Institute (NCI)NIH | 1 | Apr 17, 2026 | clinicaltrials |
| NCT03746080 | Whole Brain Radiation Therapy With Standard Temozolomide Chemo-Radiotherapy and Plerixafor in Treating Patients With Glioblastoma | completed | Phase 2 | 21 | Lawrence D RechtOTHER | 1 | Nov 14, 2025 | clinicaltrials |
| NCT01931098 | Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab | completed | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Aug 11, 2025 | clinicaltrials |
| NCT03137888 | Spectroscopic MRI-Guided Radiation Therapy Planning in Glioblastoma | completed | Phase 2 | 30 | Emory UniversityOTHER | 1 | Aug 3, 2025 | clinicaltrials |
| NCT01894061 | NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma | completed | Phase 2 | 25 | Case Comprehensive Cancer CenterOTHER | 1 | Feb 17, 2025 | clinicaltrials |
| NCT01149850 | Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma | completed | Phase 2 | 50 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT02052648 | Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors | completed | Phase 1 / Phase 2 | 160 | NewLink Genetics CorporationINDUSTRY | 1 | Mar 27, 2024 | clinicaltrials |
| NCT02661282 | Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma | completed | Phase 1 / Phase 2 | 65 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 18, 2023 | clinicaltrials |
| NCT00662506 | Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma | completed | Phase 1 / Phase 2 | 46 | National Cancer Institute (NCI)NIH | 1 | Jun 6, 2023 | clinicaltrials |
| NCT00100802 | Radiation Therapy, Temozolomide, and Lomustine in Treating Young Patients With Newly Diagnosed Gliomas | completed | Phase 2 | 118 | Children's Oncology GroupNETWORK | 1 | Feb 15, 2023 | clinicaltrials |
| NCT04657315 | Evaluation of Maximum Tolerated Dose, Safety and Efficiency of MSC11FCD Therapy to Recurrent Glioblastoma Patients(MSC11FCD-GBM) | completed | Phase 1 / Phase 2 | 10 | CHA UniversityOTHER | 1 | Jan 18, 2023 | clinicaltrials |
| NCT01730950 | Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma | completed | Phase 2 | 182 | Radiation Therapy Oncology GroupNETWORK | 1 | Dec 29, 2022 | clinicaltrials |
| NCT00731731 | Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | completed | Phase 1 / Phase 2 | 125 | National Cancer Institute (NCI)NIH | 1 | Aug 4, 2022 | clinicaltrials |
| NCT01062425 | Temozolomide and Radiation Therapy With or Without Cediranib Maleate in Treating Patients With Newly Diagnosed Glioblastoma | completed | Phase 2 | 261 | National Cancer Institute (NCI)NIH | 1 | Jul 26, 2022 | clinicaltrials |
| NCT01609790 | Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors | completed | Phase 2 | 137 | National Cancer Institute (NCI)NIH | 2 | Jul 21, 2022 | clinicaltrials |
| NCT01004874 | Avastin/Radiation (XRT)/Temozolomide (Temodar) Followed by Avastin/Temodar/Topotecan for Glioblastoma | completed | Phase 2 | 80 | Duke UniversityOTHER | 1 | Apr 13, 2022 | clinicaltrials |
| NCT01856933 | BrUOG 263: Prostate Specific Membrane Antigen (PSMA) Glioblastoma Multiforme (GBM) | completed | Phase 2 | 6 | Heinrich Elinzano, MDOTHER | 1 | Nov 23, 2021 | clinicaltrials |
| NCT01189266 | Vorinostat and Radiation Therapy Followed by Maintenance Therapy With Vorinostat in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma | completed | Phase 1 / Phase 2 | 79 | National Cancer Institute (NCI)NIH | 3 | Oct 28, 2021 | clinicaltrials |
| NCT00879437 | Valproic Acid, Radiation, and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma | completed | Phase 2 | 38 | Baylor College of MedicineOTHER | 1 | Jul 21, 2021 | clinicaltrials |
| NCT01051557 | Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma | completed | Phase 1 / Phase 2 | 36 | National Cancer Institute (NCI)NIH | 1 | Jul 19, 2021 | clinicaltrials |
| NCT02798406 | Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects(CAPTIVE) | completed | Phase 2 | 49 | DNAtrix, Inc.INDUSTRY | 2 | Jul 15, 2021 | clinicaltrials |
| NCT01740258 | Bevacizumab Beyond Progression (BBP)(BBP) | completed | Phase 2 | 68 | Duke UniversityOTHER | 1 | Jan 26, 2021 | clinicaltrials |
| NCT00052208 | Gefitinib and Radiation Therapy in Treating Patients With Glioblastoma Multiforme | completed | Phase 1 / Phase 2 | 158 | National Cancer Institute (NCI)NIH | 1 | Oct 30, 2020 | clinicaltrials |
| NCT00402116 | Phase 1/2 Study of Enzastaurin in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) Patients | completed | Phase 1 / Phase 2 | 72 | Eli Lilly and CompanyINDUSTRY | 1 | Aug 6, 2020 | clinicaltrials |
| NCT01498328 | A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma(ReACT) | completed | Phase 2 | 127 | Celldex TherapeuticsINDUSTRY | 1 | Feb 17, 2020 | clinicaltrials |
| NCT01806675 | 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy | completed | Phase 1 / Phase 2 | 25 | Sanjiv Sam GambhirOTHER | 1 | Oct 3, 2019 | clinicaltrials |
| NCT01454596 | CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII | completed | Phase 1 / Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | Aug 21, 2019 | clinicaltrials |
| NCT01514201 | Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas | completed | Phase 1 / Phase 2 | 66 | National Cancer Institute (NCI)NIH | 1 | Aug 13, 2019 | clinicaltrials |
| NCT00423735 | Dasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma | completed | Phase 2 | 64 | National Cancer Institute (NCI)NIH | 3 | Jul 24, 2019 | clinicaltrials |
| NCT00902577 | MRI and PET/FMISO In Assessing Tumor Hypoxia in Patients With Newly Diagnosed Glioblastoma Multiforme | completed | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Apr 8, 2019 | clinicaltrials |
| NCT00441142 | Zactima With Temodar During Radiation Treatment for Newly Diagnosed Stage IV Brain Tumors(Zactima) | completed | Phase 1 / Phase 2 | 119 | Patrick Y. Wen, MDOTHER | 1 | Mar 5, 2019 | clinicaltrials |
| NCT01614795 | Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma | completed | Phase 2 | 46 | National Cancer Institute (NCI)NIH | 2 | Dec 11, 2018 | clinicaltrials |
| NCT01977677 | Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma | completed | Phase 1 / Phase 2 | 30 | Lawrence RechtOTHER | 1 | Oct 23, 2018 | clinicaltrials |
| NCT00329719 | Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma | completed | Phase 1 / Phase 2 | 115 | National Cancer Institute (NCI)NIH | 1 | Oct 16, 2018 | clinicaltrials |
| NCT00433381 | Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma | completed | Phase 2 | 123 | National Cancer Institute (NCI)NIH | 1 | Sep 17, 2018 | clinicaltrials |
| NCT00107003 | GW572016 to Treat Recurrent Malignant Brain Tumors | completed | Phase 2 | 9 | National Cancer Institute (NCI)NIH | 1 | Jul 5, 2018 | clinicaltrials |
| NCT00335764 | Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma | completed | Phase 1 / Phase 2 | 92 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2018 | clinicaltrials |
| NCT01648348 | Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme | completed | Phase 1 / Phase 2 | 116 | National Cancer Institute (NCI)NIH | 1 | May 23, 2018 | clinicaltrials |
| NCT00305864 | Motexafin Gadolinium, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma | completed | Phase 1 / Phase 2 | 118 | National Cancer Institute (NCI)NIH | 1 | Mar 5, 2018 | clinicaltrials |
| NCT01753713 | Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma | completed | Phase 2 | 33 | Manmeet Ahluwalia, MDOTHER | 1 | Dec 12, 2017 | clinicaltrials |
| NCT00045708 | A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-Grade Gliomas | completed | Phase 1 / Phase 2 | 57 | National Cancer Institute (NCI)NIH | 1 | Oct 18, 2017 | clinicaltrials |
| NCT00187486 | Safety and Efficacy Study of Tarceva, Temodar, and Radiation Therapy in Patients With Newly Diagnosed Brain Tumors | completed | Phase 2 | 66 | University of California, San FranciscoOTHER | 1 | Sep 5, 2017 | clinicaltrials |
| NCT00045110 | Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma | completed | Phase 1 / Phase 2 | 136 | National Cancer Institute (NCI)NIH | 1 | Aug 17, 2017 | clinicaltrials |
| NCT00980343 | GDC-0449 in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery | completed | Phase 2 | 44 | National Cancer Institute (NCI)NIH | 1 | Aug 16, 2017 | clinicaltrials |
| NCT00540722 | Gossypol in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme | completed | Phase 2 | 56 | National Cancer Institute (NCI)NIH | 1 | Aug 11, 2017 | clinicaltrials |
| NCT00823797 | Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma | completed | Phase 2 | 45 | University of WashingtonOTHER | 1 | Jul 7, 2017 | clinicaltrials |
| NCT00379080 | Tandutinib in Treating Patients With Recurrent or Progressive Glioblastoma | completed | Phase 1 / Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Apr 7, 2017 | clinicaltrials |
| NCT00883298 | Bi-weekly Temozolomide Plus Bevacizumab for Adult Patients With Recurrent Glioblastoma Multiforme | completed | Phase 2 | 30 | Center for Neurosciences, TucsonOTHER | 1 | Mar 30, 2017 | clinicaltrials |
Data updated 4 days agoSource updated Sep 23, 2026source: clinicaltrials